2020
Abnormalities of Aspiration and Swallowing Function in Survivors of Acute Respiratory Failure
Langmore SE, Krisciunas GP, Warner H, White SD, Dvorkin D, Fink D, McNally E, Scheel R, Higgins C, Levitt JE, McKeehan J, Deane S, Siner JM, Vojnik R, Moss M. Abnormalities of Aspiration and Swallowing Function in Survivors of Acute Respiratory Failure. Dysphagia 2020, 36: 831-841. PMID: 33156398, DOI: 10.1007/s00455-020-10199-8.Peer-Reviewed Original ResearchConceptsAcute respiratory failureRespiratory failureARF survivorsMechanical ventilationMultivariable analysisUniversity-based tertiary medical centerPenetration-Aspiration Scale scoresUpper airway edemaProspective cohort studyTertiary medical centerLaryngeal structuresFlexible endoscopic evaluationAirway edemaARF patientsSecondary outcomesCohort studyFunction abnormalitiesPrimary outcomeEndoscopic evaluationPharyngeal weaknessSwallowing examinationSwallowing functionIntensive carePhysiologic abnormalitiesUnivariate analysisLeft atrial strain and diastolic function abnormalities in obese and type 2 diabetic adolescents and young adults
Steele JM, Urbina EM, Mazur WM, Khoury PR, Nagueh SF, Tretter JT, Alsaied T. Left atrial strain and diastolic function abnormalities in obese and type 2 diabetic adolescents and young adults. Cardiovascular Diabetology 2020, 19: 163. PMID: 33004030, PMCID: PMC7531140, DOI: 10.1186/s12933-020-01139-9.Peer-Reviewed Original ResearchConceptsConduit strain rateDiastolic function abnormalitiesLV diastolic functionDiastolic functionFunction abnormalitiesT2DM patientsYoung adultsLA volumeMultivariable analysisBooster strainLeft ventricular diastolic function abnormalitiesType 2 diabetic adolescentsType 2 diabetes mellitusMitral E/Normal LA volumePrevalence of diastolicStructurally normal heartsPrevalence of abnormalitiesSpeckle tracking measurementsAtrial strainAtrial functionDiabetes mellitusEchocardiographic measuresEjection fractionHeart failureImpact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O’Dorisio T, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2372-2382. PMID: 32123969, PMCID: PMC7396396, DOI: 10.1007/s00259-020-04709-x.Peer-Reviewed Original ResearchConceptsLiver tumor burdenProgression-free survivalLargest target lesionHigher liver tumour burdenTumor burdenMidgut neuroendocrine tumorsAlkaline phosphatase elevationNeuroendocrine tumorsTarget lesionsLesion sizeHazard ratioTreatment outcomesAnalysis of PFSHigh-dose octreotide LARMedian progression-free survivalImproved progression-free survivalNETTER-1 studyNETTER-1 trialLiver function abnormalitiesKaplan-Meier estimatesOctreotide LARPrimary endpointFunction abnormalitiesBaseline factorsCox regression
2018
Effectiveness of alternative dose fingolimod for multiple sclerosis
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology Clinical Practice 2018, 8: 102-107. PMID: 29708225, PMCID: PMC5914753, DOI: 10.1212/cpj.0000000000000434.Peer-Reviewed Original ResearchProportion of patientsDaily doseMultiple sclerosisAlternate doseAdverse eventsDisease activityProfound lymphopeniaContrast-enhancing MRI lesionsAlternate dosingLiver function abnormalitiesClass IV evidenceDaily oral medicationContrast-enhancing lesionsBetter disease controlBreakthrough diseaseMRI lesionsRadiologic outcomesFunction abnormalitiesMost patientsOral medicationsRelapse rateFrequent dosingObservational studyFingolimodHigh risk
2010
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 4953-4960. PMID: 20940188, PMCID: PMC4676802, DOI: 10.1200/jco.2010.30.8338.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBenzoquinonesCarcinoma, Non-Small-Cell LungErbB ReceptorsFemaleGene RearrangementHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicLung NeoplasmsMaleMiddle AgedMutationProspective StudiesProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesConceptsObjective response rateProgression-free survivalCell lung cancerIPI-504Lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor therapyUnited States cancer centersTyrosine kinase inhibitor therapyState Cancer CenterCommon adverse eventsLiver function abnormalitiesPhase II studyOverall study populationKinase inhibitor therapyHeat shock protein 90 inhibitorNovel heat shock protein 90 inhibitorALK gene rearrangementStable diseaseAdvanced NSCLCAdverse eventsFunction abnormalitiesII studyPartial responseInhibitor therapyPrimary outcomeMRI and Computed Tomography of Cardiac and Pulmonary Complications of Tetralogy of Fallot in Adults
Gartner R, Sutton N, Weinstein S, Spindola-Franco H, Haramati L. MRI and Computed Tomography of Cardiac and Pulmonary Complications of Tetralogy of Fallot in Adults. Journal Of Thoracic Imaging 2010, 25: 183-190. PMID: 20216461, DOI: 10.1097/rti.0b013e31819d14fe.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTetralogy of FallotCongenital heart diseaseHeart diseasePeripheral pulmonary artery stenosisCyanotic congenital heart diseasePulmonary function abnormalitiesLong-term sequelaePulmonary artery stenosisPulmonary complicationsFunction abnormalitiesArtery stenosisImaging findingsMedical managementSurgical outcomesUncommon findingSurgical techniqueComputed tomographyComplicationsDiagnostic valueDiseaseCommon formAdultsFallotPatientsTetralogy
2009
Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism
Trow TK, Taichman DB. Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism. Respiratory Medicine 2009, 103: 951-962. PMID: 19304472, DOI: 10.1016/j.rmed.2009.02.016.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionEndothelin receptor antagonistsArterial hypertensionET-1Development of PAHManagement of PAHPathogenesis of PAHEndothelin receptor blockadeLiver function abnormalitiesPlacebo-controlled trialNitric oxide-mediated pathwayClinical study resultsGood clinical resultsClinical treatment studiesUnited States FoodPeripheral edemaFunction abnormalitiesReceptor blockadeDual antagonismDual blockadeSafety profileET receptorsEndothelin-1Head studiesReceptor antagonist
2002
Effects of Development on Olanzapine-Associated Adverse Events
WOODS SW, MARTIN A, SPECTOR SG, MCGLASHAN TH. Effects of Development on Olanzapine-Associated Adverse Events. Journal Of The American Academy Of Child & Adolescent Psychiatry 2002, 41: 1439-1446. PMID: 12447030, DOI: 10.1097/00004583-200212000-00015.Peer-Reviewed Original ResearchConceptsLiver function abnormalitiesAdverse eventsFunction abnormalitiesAtypical antipsychoticsComplaint riskWeight gainAtypical antipsychotic medicationsExtrapyramidal syndromeTardive dyskinesiaProlactin increaseAntipsychotic medicationAdolescent patientsRisk ratioPatient exposureSurveillance databaseAge groupsOlanzapineComplaintsConfidence intervalsExposure estimatesAntipsychoticsSedationPatientsChildrenAdults
1999
Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders
Potenza M, Holmes J, Kanes S, McDougle C. Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. Journal Of Clinical Psychopharmacology 1999, 19: 37-44.. PMID: 9934941, DOI: 10.1097/00004714-199902000-00008.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical Global Impression ScaleWeight gainTolerability of olanzapineLiver function abnormalitiesExtrapyramidal side effectsGlobal Impression ScaleGlobal improvement itemTreatment of childrenSignificant adverse effectsDevelopmental disordersSelf-injurious behaviorClinical respondersOlanzapine treatmentFunction abnormalitiesDaily doseOverall symptomsPatient populationImpression ScalePrincipal diagnosisMotor restlessnessProspective fashionWeek 4Related symptomsSide effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply